Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wave Life Sciences Ltd. (WVE)
USD5.95
-0.18 (-2.99%)
SG NASDAQ Healthcare Biotechnology
Address
Marina One East Tower 18936
Singapore, MA, SG
Singapore, MA, SG
CEO
Paul Bolno
Website
wavelifesciences.com
IPO
2015-11-11
CIK 1631574 ISIN SG9999014716
Description
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.95
-0.18 (-2.99%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
-1.33
Float Shares
157.83M
Free Float %
82.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.70% | +3.13% | -6.80% | -52.76% | -15.21% | -61.29% | +5.28% | +66.16% | -2.23% | -58.64% | -58.88% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (25 ratings, all time)
Buy
Price Targets & DCF
Current price
5.95
Low
13.00
+118.6%
Consensus
26.38
+343.6%
Median
28.00
+370.9%
High
43.00
+623.1%
DCF (Unlevered)
0.66
-88.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 14 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
13.50
+127.0%
|
| Last Quarter | 6 |
15.17
+155.1%
|
| Last Year | 25 |
26.28
+341.9%
|
| All Time | 35 |
24.31
+308.8%
|
Quality scores
Altman Z-Score
7.45
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-60.6% Q1'26: +316.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-72.9% Q1'26: +55.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-498.9% Q1'26: -156.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-478.3% Q1'26: -81.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +730.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+22.0% Q1'26: +23.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.14× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 11 EPS Ana. |
Dec 2027 12 Rev. Ana. 11 EPS Ana. |
Dec 2028 13 Rev. Ana. 11 EPS Ana. |
Dec 2029 12 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
152.0K
est: 200.0K (-24.0%)
|
1.49M
est: 1.11M (+33.7%)
|
3.70M
est: 2.65M (+39.8%)
|
14.41M
est: 16.72M (-13.8%)
|
15.98M
est: 18.94M (-15.6%)
|
20.08M
est: 20.48M (-2.0%)
|
40.96M
est: 52.67M (-22.2%)
|
3.65M
est: 9.40M (-61.2%)
|
113.31M
est: 112.91M (+0.3%)
|
108.30M
est: 54.07M (+100.3%)
|
42.73M
est: 41.01M (+4.2%)
|
57.76M
43.59M – 89.58M
+40.8% YoY
|
56.25M
2.44M – 83.01M
-2.6% YoY
|
114.17M
111.28M – 117.07M
+103.0% YoY
|
256.06M
120.42M – 405.83M
+124.3% YoY
|
539.36M
253.65M – 854.83M
+110.6% YoY
|
| EBITDA |
-18.56M
est: -178.3K (-10,308.7%)
|
-54.94M
est: -990.4K (-5,446.8%)
|
-100.24M
est: -2.36M (-4,142.1%)
|
-153.94M
est: -14.91M (-932.6%)
|
-200.73M
est: -16.89M (-1,088.5%)
|
-145.26M
est: -18.26M (-695.4%)
|
-117.18M
est: -46.97M (-149.5%)
|
-152.61M
est: -8.38M (-1,720.2%)
|
-58.79M
est: -100.68M (+41.6%)
|
-101.74M
est: -48.21M (-111.0%)
|
-195.53M
est: -36.57M (-434.6%)
|
-51.50M
-79.87M – -38.87M
-40.8% YoY
|
-50.16M
-74.02M – -2.18M
+2.6% YoY
|
-101.80M
-104.38M – -99.22M
-103.0% YoY
|
-228.32M
-361.86M – -107.37M
-124.3% YoY
|
-480.92M
-762.22M – -226.17M
-110.6% YoY
|
| EBIT |
-19.30M
est: -184.0K (-10,387.8%)
|
-55.72M
est: -1.02M (-5,352.5%)
|
-102.39M
est: -2.44M (-4,099.7%)
|
-159.52M
est: -15.38M (-937.1%)
|
-208.32M
est: -17.43M (-1,095.4%)
|
-153.38M
est: -18.84M (-713.9%)
|
-127.02M
est: -48.46M (-162.1%)
|
-162.72M
est: -8.65M (-1,781.0%)
|
-68.00M
est: -103.88M (+34.5%)
|
-110.40M
est: -49.74M (-122.0%)
|
-204.38M
est: -37.73M (-441.6%)
|
-53.14M
-82.42M – -40.11M
-40.8% YoY
|
-51.75M
-76.37M – -2.25M
+2.6% YoY
|
-105.04M
-107.71M – -102.38M
-103.0% YoY
|
-235.58M
-373.38M – -110.79M
-124.3% YoY
|
-496.22M
-786.47M – -233.36M
-110.6% YoY
|
| Net Income |
-19.20M
est: -217.10M (+91.2%)
|
-55.40M
est: -327.03M (+83.1%)
|
-102.04M
est: -521.31M (+80.4%)
|
-146.65M
est: -693.46M (+78.9%)
|
-193.64M
est: -754.21M (+74.3%)
|
-149.91M
est: -518.89M (+71.1%)
|
-122.25M
est: -307.37M (+60.2%)
|
-161.82M
est: -278.17M (+41.8%)
|
-57.51M
est: -61.67M (+6.7%)
|
-97.01M
est: -187.56M (+48.3%)
|
-204.38M
est: -201.03M (-1.7%)
|
-184.65M
-214.97M – -163.25M
+8.1% YoY
|
-243.67M
-286.01M – -158.06M
-32.0% YoY
|
-256.08M
-348.14M – -17.58M
-5.1% YoY
|
-104.56M
-184.07M – -32.56M
+59.2% YoY
|
36.14M
11.25M – 63.62M
+134.6% YoY
|
| SGA |
10.39M
est: 723.3K (+1,336.8%)
|
15.99M
est: 4.02M (+298.1%)
|
26.98M
est: 9.58M (+181.5%)
|
39.51M
est: 60.47M (-34.7%)
|
48.87M
est: 68.50M (-28.7%)
|
42.51M
est: 74.08M (-42.6%)
|
46.11M
est: 190.51M (-75.8%)
|
50.51M
est: 34.01M (+48.5%)
|
51.29M
est: 400.38M (-87.2%)
|
59.02M
est: 191.71M (-69.2%)
|
75.33M
est: 145.43M (-48.2%)
|
204.81M
154.58M – 317.64M
+40.8% YoY
|
199.46M
8.65M – 294.35M
-2.6% YoY
|
404.84M
394.57M – 415.11M
+103.0% YoY
|
907.95M
426.99M – 1.44B
+124.3% YoY
|
1.91B
899.41M – 3.03B
+110.6% YoY
|
| EPS |
-0.89
est: -1.57 (+43.3%)
|
-2.43
est: -2.37 (-2.7%)
|
-3.85
est: -3.77 (-2.1%)
|
-5.06
est: -5.02 (-0.9%)
|
-5.30
est: -5.45 (+2.8%)
|
-3.82
est: -3.75 (-1.8%)
|
-2.36
est: -2.22 (-6.2%)
|
-2.05
est: -2.01 (-1.9%)
|
-0.54
est: -0.55 (+1.1%)
|
-0.70
est: -1.14 (+38.4%)
|
-1.21
est: -1.19 (-1.5%)
|
-1.11
-1.27 – -0.97
+6.7% YoY
|
-1.29
-1.70 – -0.94
-16.4% YoY
|
-1.17
-2.06 – -0.10
+9.3% YoY
|
-0.62
-1.09 – -0.19
+47.2% YoY
|
0.21
0.07 – 0.38
+134.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-20 | Wells Fargo | Overweight | Overweight | Maintain |
| 2026-05-19 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-05-04 | Citigroup | Buy | Buy | Maintain |
| 2026-04-30 | Canaccord Genuity | Buy | Buy | Maintain |
| 2026-04-29 | Truist Securities | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-209.10M
OE per share TTM
-1.18
Owner's Yield
-15.88%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
77.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
252
Total invested
1.25B
Insider transactions (90d)
0
Beneficial owners (>5%)
44
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GSK plc | 10.68M | 10.95% | 10.68M | — | 10.68M | 10.68M | CO | England and Wales | 2023-01-30 | ↗ |
| 2 | (1)Names of reporting persons. BlackRock, Inc. | 7.30M | 5.00% | — | — | 7.30M | — | HC | Delaware | 2024-10-18 | ↗ |
| 3 | 75-2686461 | 5.59M | 9.50% | — | 5.59M | — | 5.59M | HC | — | 2022-02-14 | ↗ |
| 4 | III | 5.59M | 9.50% | — | 5.59M | — | 5.59M | IN | — | 2022-02-14 | ↗ |
| 5 | Ltd. – 75-2482446 | 5.59M | 9.50% | — | 5.59M | — | 5.59M | IA | — | 2022-02-14 | ↗ |
| 6 | Adage Capital Advisors, L.L.C. | 5.53M | 6.36% | — | 5.53M | — | — | OO | Delaware | 2022-12-22 | ↗ |
| 7 | Adage Capital Partners GP, L.L.C. | 5.53M | 6.36% | — | 5.53M | — | — | OO | Delaware | 2022-12-22 | ↗ |
| 8 | Adage Capital Partners, L.P. | 5.53M | 6.36% | — | 5.53M | — | — | PN | Delaware | 2022-12-22 | ↗ |
| 9 | Phillip Gross | 5.53M | 6.36% | — | 5.53M | — | — | IN | United States | 2022-12-22 | ↗ |
| 10 | Robert Atchinson | 5.53M | 6.36% | — | 5.53M | — | — | IN | United States | 2022-12-22 | ↗ |
| 11 | Deerfield Management Company, L.P. | 3.91M | 7.98% | — | 3.91M | — | — | PN | Delaware | 2021-04-09 | ↗ |
| 12 | Deerfield Mgmt, L.P. | 3.91M | 7.98% | — | 3.91M | — | — | PN | Delaware | 2021-04-09 | ↗ |
| 13 | Deerfield Partners, L.P. | 3.91M | 7.98% | — | 3.91M | — | — | PN | Delaware | 2021-04-09 | ↗ |
| 14 | James E. Flynn | 3.91M | 7.98% | — | 3.91M | — | — | IN | Delaware | 2021-04-09 | ↗ |
| 15 | M28 Capital Management LP | 3.77M | 7.20% | — | 3.77M | — | — | IA | Delaware, USA | 2021-10-29 | ↗ |
| 16 | 683 Capital Management, LLC | 3.63M | 5.90% | — | 3.63M | — | 3.63M | IA | United States of America | 2022-05-26 | ↗ |
| 17 | 683 Capital Partners, LP | 3.63M | 5.90% | — | 3.63M | — | 3.63M | PN | United States of America | 2022-05-26 | ↗ |
| 18 | Ari Zweiman | 3.63M | 5.90% | — | 3.63M | — | 3.63M | IN | United States of America | 2022-05-26 | ↗ |
| 19 | Daniel Mack | 3.36M | 6.90% | — | 3.36M | — | — | HC | MA | 2021-02-16 | ↗ |
| 20 | Nantahala Capital Management, LLC | 3.36M | 6.90% | — | 3.36M | — | — | IA | MA | 2021-02-16 | ↗ |
| 21 | Wilmot B. Harkey | 3.36M | 6.90% | — | 3.36M | — | — | HC | MA | 2021-02-16 | ↗ |
| 22 | Wellington Group Holdings LLP | 3.21M | 9.35% | — | 3.02M | — | — | HC | Massachusetts | 2020-01-28 | ↗ |
| 23 | Wellington Investment Advisors Holdings LLP | 3.21M | 9.35% | — | 3.02M | — | — | HC | Massachusetts | 2020-01-28 | ↗ |
| 24 | Wellington Management Group LLP | 3.21M | 9.35% | — | 3.02M | — | — | HC | Massachusetts | 2020-01-28 | ↗ |
| 25 | Wellington Management Company LLP | 3.04M | 8.86% | — | 2.98M | — | — | IA | Massachusetts | 2020-01-28 | ↗ |
| 26 | First Trust Portfolios L.P., First Trust Advisors L.P., The Charger Corporation | 2.71M | 5.98% | — | 1.64M | — | 1.64M | BD, IA, HC | Jersey Channel Islands | 2019-02-13 | ↗ |
| 27 | Redmile Group, LLC | 2.24M | 7.60% | — | 2.24M | — | 2.24M | IA, OO | Delaware | 2019-02-14 | ↗ |
| 28 | JEREMY C. GREEN | 2.21M | 7.95% | — | 2.21M | — | — | HC, IN | UNITED KINGDOM | 2018-02-14 | ↗ |
| 29 | BB Biotech AG | 1.90M | 5.50% | — | 1.90M | — | 1.90M | HC, CO | Switzerland | 2019-12-23 | ↗ |
| 30 | Biotech Target N.V. | 1.90M | 5.50% | — | 1.90M | — | 1.90M | CO | Switzerland | 2019-12-23 | ↗ |
| 31 | ( 13-5315170 | 1.88M | 11.00% | — | 1.88M | — | 1.88M | CO | Nerlands | 2016-05-12 | ↗ |
| 32 | ( 52-2090275 | 1.88M | 11.00% | — | 1.88M | — | 1.88M | OO | Nerlands | 2016-05-12 | ↗ |
| 33 | ( 98-0182045 | 1.88M | 11.00% | — | 1.88M | — | 1.88M | PN | Nerlands | 2016-05-12 | ↗ |
| 34 | 52-2090292 | 1.88M | 11.00% | — | 1.88M | — | 1.88M | OO | Nerlands | 2016-05-12 | ↗ |
| 35 | Teva Pharmaceutical Industries Limited (98-0478099) | 1.88M | 9.00% | — | 1.88M | — | — | CO | Israel | 2015-12-10 | ↗ |
| 36 | Teva Pharmaceuticals USA, Inc. (22-1734359) | 1.88M | 9.00% | — | 1.88M | — | — | CO | Delaware | 2015-12-10 | ↗ |
| 37 | Boxer Asset Management Inc. | 1.59M | 5.50% | — | 1.59M | — | 1.59M | CO | Delaware | 2018-06-29 | ↗ |
| 38 | Boxer Capital, LLC | 1.59M | 5.50% | — | 1.59M | — | 1.59M | OO | Delaware | 2018-06-29 | ↗ |
| 39 | Joe Lewis | 1.59M | 5.50% | — | 1.59M | — | 1.59M | IN | Delaware | 2018-06-29 | ↗ |
| 40 | Foresite Capital Fund III, L.P. (“FCF III”) | 1.33M | 6.40% | 1.33M | — | 1.33M | — | PN | Delaware | 2015-11-19 | ↗ |
| 41 | Foresite Capital Management III, LLC (“FCM III”) | 1.33M | 6.40% | 1.33M | — | 1.33M | — | OO | Delaware | 2015-11-19 | ↗ |
| 42 | James Tananbaum (“Tananbaum”) | 1.33M | 6.40% | 1.33M | — | 1.33M | — | IN | Delaware | 2015-11-19 | ↗ |
| 43 | Morgan Stanley | 1.25M | 2.60% | — | 1.24M | — | 1.25M | HC, CO | Delaware. | 2021-02-12 | ↗ |
| 44 | Morgan Stanley Capital Services LLC | 1.22M | 2.50% | — | 1.22M | — | 1.22M | CO | Delaware. | 2021-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
252
+14 vs prev Q
New positions
51
Closed positions
37
Increased
155
Reduced
51
Put/Call ratio
0.31
Calls held
3.66M
Puts held
1.15M
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 447.8K +447.8K (+100.0%) | 7.61B +7.6B (+100.0%) | 0.27% +0.267 pp | 2.25% +2.247 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 203.7K +203.7K (+100.0%) | 3.46B +3.5B (+100.0%) | 0.12% +0.122 pp | 0.01% +0.005 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 3 | GSK PLC | 18.25M +18.2M (+100.0%) | 310.18M +310.2M (+100.0%) | 10.88% +10.877 pp | 38.82% +38.820 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 18.20M +1.0K (+0.0%) | 309.45M +176.2M (+132.3%) | 10.85% -0.248 pp | 3.17% +1.529 pp | USD7.38 +130.4% | 41 qtrs — |
| 5 | FMR LLC | 15.14M +10.0M (+195.0%) | 257.31M +219.8M (+585.2%) | 9.02% +5.895 pp | 0.01% +0.011 pp | USD13.73 +23.8% | 16 qtrs — |
| 6 | BLACKROCK, INC. | 12.65M +2.2M (+21.3%) | 215.03M +138.7M (+181.6%) | 7.54% +1.180 pp | 0.00% +0.002 pp | USD10.32 +64.7% | 6 qtrs — |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.79M -4.8M (-32.8%) | 166.36M +59.7M (+56.0%) | 5.83% -3.049 pp | 0.25% +0.083 pp | USD7.01 +142.5% | 18 qtrs — |
| 8 | MAVERICK CAPITAL LTD | 9.28M +888.4K (+10.6%) | 157.76M +96.3M (+156.8%) | 5.53% +0.415 pp | 1.69% +0.872 pp | USD7.80 +117.9% | 20 qtrs — |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 7.41M +3.4M (+83.1%) | 125.93M +96.3M (+325.3%) | 4.42% +1.950 pp | 0.01% +0.010 pp | USD12.39 +37.2% | 38 qtrs — |
| 10 | DARWIN GLOBAL MANAGEMENT, LTD. | 7.30M +7.3M (+100.0%) | 125.17M +125.2M (+100.0%) | 4.35% +4.351 pp | 2.53% +2.534 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 11 | DRIEHAUS CAPITAL MANAGEMENT LLC | 6.58M +283.0K (+4.5%) | 111.88M +65.8M (+142.7%) | 3.92% +0.083 pp | 0.76% +0.430 pp | USD8.64 +96.8% | 9 qtrs — |
| 12 | M28 CAPITAL MANAGEMENT LP | 5.66M +— (+0.0%) | 96.30M +54.8M (+132.2%) | 3.38% -0.077 pp | 70.00% +9.027 pp | USD6.54 +159.9% | 17 qtrs — |
| 13 | FEDERATED HERMES, INC. | 4.74M +993.8K (+26.5%) | 80.66M +53.2M (+193.8%) | 2.83% +0.541 pp | 0.13% +0.086 pp | USD9.35 +81.8% | 5 qtrs — |
| 14 | PRIMECAP MANAGEMENT CO/CA/ | 4.10M +2.2M (+115.7%) | 69.62M +55.7M (+400.9%) | 2.44% +1.284 pp | 0.05% +0.042 pp | USD12.43 +36.8% | 26 qtrs — |
| 15 | 683 CAPITAL MANAGEMENT, LLC | 4.02M -135.0K (-3.3%) | 68.26M +37.9M (+124.7%) | 2.39% -0.137 pp | 2.97% +1.383 pp | USD3.64 +367.0% | 19 qtrs — |
| 16 | VANGUARD GROUP INC | 3.57M +433.9K (+13.8%) | 60.75M +37.8M (+164.3%) | 2.13% +0.216 pp | 0.00% +0.001 pp | USD9.47 +79.5% | 40 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 3.17M +251.7K (+8.6%) | 53.90M +32.5M (+152.3%) | 1.89% +0.110 pp | 0.00% +0.002 pp | USD8.15 +108.6% | 41 qtrs — |
| 18 | STATE STREET CORP | 3.00M +149.7K (+5.3%) | 50.93M +30.1M (+144.5%) | 1.79% +0.050 pp | 0.00% +0.001 pp | USD6.71 +153.4% | 39 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 2.85M +728.9K (+34.3%) | 48.52M +33.0M (+211.9%) | 1.70% +0.406 pp | 0.01% +0.004 pp | USD9.82 +73.1% | 33 qtrs — |
| 20 | AFFINITY ASSET ADVISORS, LLC | 2.70M +600.0K (+28.6%) | 45.90M +30.5M (+198.6%) | 1.61% +0.329 pp | 2.62% +1.276 pp | USD9.86 +72.4% | 8 qtrs — |
| 21 | EMERALD ADVISERS, LLC | 2.46M -541.8K (-18.1%) | 41.74M +19.8M (+90.3%) | 1.46% -0.364 pp | 1.29% +0.583 pp | USD6.25 +172.0% | 7 qtrs — |
| 22 | SIREN, L.L.C. | 2.45M -1.2M (-33.7%) | 41.65M +14.6M (+53.9%) | 1.46% -0.793 pp | 1.24% +0.184 pp | USD8.20 +107.3% | 6 qtrs — |
| 23 | KYNAM CAPITAL MANAGEMENT, LP | 2.17M -2.4M (-52.4%) | 36.87M +3.5M (+10.5%) | 1.29% -1.488 pp | 2.36% -0.130 pp | USD7.08 +140.1% | 17 qtrs — |
| 24 | LOOMIS SAYLES & CO L P | 2.04M -865.2K (-29.8%) | 34.68M +13.4M (+63.1%) | 1.22% -0.556 pp | 0.04% +0.017 pp | USD9.83 +72.9% | 5 qtrs — |
| 25 | PFIZER INC | 1.88M +— (+0.0%) | 31.88M +18.2M (+132.2%) | 1.12% -0.026 pp | 13.48% +10.342 pp | USD12.37 +37.4% | 5 qtrs — |
| 26 | FIRST LIGHT ASSET MANAGEMENT, LLC | 1.85M +1.9M (+100.0%) | 31.52M +31.5M (+100.0%) | 1.11% +1.105 pp | 2.41% +2.410 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 27 | BELLEVUE GROUP AG | 1.49M -2.6M (-63.6%) | 25.34M -4.6M (-15.5%) | 0.89% -1.608 pp | 0.48% -0.143 pp | USD12.23 +39.0% | 27 qtrs — |
| 28 | EMERALD MUTUAL FUND ADVISERS TRUST | 1.41M -351.4K (-19.9%) | 24.05M +11.1M (+86.0%) | 0.84% -0.234 pp | 1.17% +0.504 pp | USD5.66 +200.4% | 7 qtrs — |
| 29 | RTW INVESTMENTS, LP | 1.35M +450.0K (+50.0%) | 22.95M +16.4M (+248.4%) | 0.80% +0.256 pp | 0.23% +0.149 pp | USD11.13 +52.7% | 6 qtrs — |
| 30 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.19M +193.0K (+19.3%) | 20.25M +12.9M (+177.1%) | 0.71% +0.101 pp | 0.00% +0.002 pp | USD9.28 +83.2% | 39 qtrs — |
| 31 | NORTHERN TRUST CORP | 1.03M +21.3K (+2.1%) | 17.56M +10.2M (+137.1%) | 0.62% -0.001 pp | 0.00% +0.001 pp | USD7.60 +123.7% | 41 qtrs — |
| 32 | SCHRODER INVESTMENT MANAGEMENT GROUP | 1.01M +450.4K (+81.1%) | 17.25M +13.3M (+335.6%) | 0.60% +0.261 pp | 0.01% +0.010 pp | USD11.87 +43.2% | 4 qtrs — |
| 33 | JPMORGAN CHASE & CO | 892.9K +32.7K (+3.8%) | 15.18M +8.9M (+141.1%) | 0.53% +0.008 pp | 0.00% +0.001 pp | USD9.17 +85.4% | 37 qtrs — |
| 34 | SQUAREPOINT OPS LLC | 883.6K +610.0K (+223.0%) | 15.02M +13.0M (+650.0%) | 0.53% +0.360 pp | 0.02% +0.014 pp | USD14.14 +20.2% | 5 qtrs — |
| 35 | PICTET ASSET MANAGEMENT HOLDING SA | 805.9K +790.2K (+5,024.6%) | 13.83M +13.7M (+11,914.1%) | 0.48% +0.471 pp | 0.01% +0.013 pp | USD16.80 +1.2% | 7 qtrs — |
| 36 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 785.7K +675.6K (+613.6%) | 13.36M +12.6M (+1,557.3%) | 0.47% +0.401 pp | 0.00% +0.001 pp | USD15.70 +8.3% | 28 qtrs — |
| 37 | CITADEL ADVISORS LLC | 772.7K +662.9K (+603.7%) | 13.14M +12.3M (+1,534.4%) | 0.46% +0.394 pp | 0.00% +0.002 pp | USD15.62 +8.8% | 28 qtrs — |
| 38 | TWO SIGMA INVESTMENTS, LP | 749.4K +186.4K (+33.1%) | 12.74M +8.6M (+209.1%) | 0.45% +0.104 pp | 0.02% +0.012 pp | USD10.72 +58.6% | 9 qtrs — |
| 39 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 722.2K +722.2K (+100.0%) | 12.28M +12.3M (+100.0%) | 0.43% +0.431 pp | 0.04% +0.043 pp | USD17.00 +0.0% | 5 qtrs — |
| 40 | TANG CAPITAL MANAGEMENT LLC | 600.0K +600.0K (+100.0%) | 10.20M +10.2M (+100.0%) | 0.36% +0.358 pp | 0.50% +0.504 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 41 | MILLENNIUM MANAGEMENT LLC | 584.6K +193.9K (+49.6%) | 9.94M +7.1M (+247.5%) | 0.35% +0.110 pp | 0.00% +0.003 pp | USD10.02 +69.7% | 35 qtrs — |
| 42 | JANE STREET GROUP, LLC | 574.4K +77.4K (+15.6%) | 9.76M +6.1M (+168.4%) | 0.34% +0.039 pp | 0.00% +0.001 pp | USD8.62 +97.2% | 5 qtrs — |
| 43 | EVENTIDE ASSET MANAGEMENT, LLC | 500.0K +500.0K (+100.0%) | 8.50M +8.5M (+100.0%) | 0.30% +0.298 pp | 0.13% +0.133 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 44 | KENNEDY CAPITAL MANAGEMENT LLC | 492.4K -48.0K (-8.9%) | 8.37M +4.4M (+111.6%) | 0.29% -0.036 pp | 0.18% +0.090 pp | USD7.27 +133.8% | 3 qtrs — |
| 45 | EXOME ASSET MANAGEMENT LLC | 421.5K +421.5K (+100.0%) | 7.17M +7.2M (+100.0%) | 0.25% +0.251 pp | 3.43% +3.426 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 46 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 411.5K +42.8K (+11.6%) | 7.00M +4.3M (+159.2%) | 0.25% +0.021 pp | 0.01% +0.007 pp | USD12.72 +33.6% | 5 qtrs — |
| 47 | MORGAN STANLEY | 409.7K -97.6K (-19.2%) | 6.96M +3.3M (+87.5%) | 0.24% -0.065 pp | 0.00% +0.000 pp | USD8.01 +112.2% | 41 qtrs — |
| 48 | SPHERA FUNDS MANAGEMENT LTD. | 408.2K +358.2K (+716.3%) | 6.94M +6.6M (+1,795.9%) | 0.24% +0.213 pp | 1.34% +1.264 pp | USD15.81 +7.5% | 2 qtrs — |
| 49 | AMERIPRISE FINANCIAL INC | 398.4K +290.6K (+269.4%) | 6.77M +6.0M (+757.8%) | 0.24% +0.172 pp | 0.00% +0.001 pp | USD14.38 +18.2% | 9 qtrs — |
| 50 | F/M INVESTMENTS LLC | 395.9K +77.8K (+24.5%) | 6.73M +4.4M (+189.0%) | 0.24% +0.042 pp | 0.26% +0.166 pp | USD12.13 +40.1% | 5 qtrs — |
| 51 | TREXQUANT INVESTMENT LP | 391.1K +391.1K (+100.0%) | 6.65M +6.6M (+100.0%) | 0.23% +0.233 pp | 0.06% +0.059 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 52 | WALLEYE CAPITAL LLC | 378.8K -351.8K (-48.2%) | 6.44M +1.1M (+20.4%) | 0.23% -0.220 pp | 0.02% 0.000 pp | USD7.70 +120.8% | 10 qtrs — |
| 53 | WELLINGTON MANAGEMENT GROUP LLP | 365.2K -64.4K (-15.0%) | 6.21M +3.1M (+97.4%) | 0.22% -0.044 pp | 0.00% +0.001 pp | USD6.76 +151.5% | 13 qtrs — |
| 54 | BOONE CAPITAL MANAGEMENT LLC | 352.1K +352.1K (+100.0%) | 5.99M +6.0M (+100.0%) | 0.21% +0.210 pp | 1.88% +1.879 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 55 | WOODLINE PARTNERS LP | 350.5K +350.5K (+100.0%) | 5.96M +6.0M (+100.0%) | 0.21% +0.209 pp | 0.02% +0.023 pp | USD17.00 +0.0% | 14 qtrs — |
| 56 | BAKER BROS. ADVISORS LP | 344.1K +— (+0.0%) | 5.85M +3.3M (+132.2%) | 0.21% -0.005 pp | 0.03% +0.016 pp | USD8.20 +107.3% | 6 qtrs — |
| 57 | JACOBS LEVY EQUITY MANAGEMENT, INC | 338.5K +338.5K (+100.0%) | 5.76M +5.8M (+100.0%) | 0.20% +0.202 pp | 0.02% +0.022 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 58 | NUVEEN, LLC | 332.7K +83.3K (+33.4%) | 5.66M +3.8M (+209.8%) | 0.20% +0.046 pp | 0.00% +0.001 pp | USD9.37 +81.4% | 4 qtrs — |
| 59 | JAIN GLOBAL LLC | 328.1K +328.1K (+100.0%) | 5.58M +5.6M (+100.0%) | 0.20% +0.196 pp | 0.03% +0.027 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 60 | BANK OF NEW YORK MELLON CORP | 321.4K +23.6K (+7.9%) | 5.46M +3.3M (+150.6%) | 0.19% +0.010 pp | 0.00% +0.001 pp | USD7.50 +126.7% | 39 qtrs — |
| 61 | JUMP FINANCIAL, LLC | 313.5K +313.5K (+100.0%) | 5.33M +5.3M (+100.0%) | 0.19% +0.187 pp | 0.07% +0.066 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 62 | NEWTYN MANAGEMENT, LLC | 300.0K +— (+0.0%) | 5.10M +2.9M (+132.2%) | 0.18% -0.004 pp | 0.54% +0.267 pp | USD6.95 +144.6% | 15 qtrs — |
| 63 | HRT FINANCIAL LP | 299.7K +299.7K (+100.0%) | 5.10M +5.1M (+100.0%) | 0.18% +0.179 pp | 0.02% +0.016 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 64 | CAPTION MANAGEMENT, LLC | 284.4K +100.0K (+54.2%) | 4.83M +3.5M (+258.2%) | 0.17% +0.057 pp | 0.03% +0.023 pp | USD10.82 +57.1% | 4 qtrs — |
| 65 | MOODY ALDRICH PARTNERS LLC | 274.4K -76.1K (-21.7%) | 4.67M +2.1M (+81.8%) | 0.16% -0.050 pp | 0.87% +0.384 pp | USD7.89 +115.5% | 7 qtrs — |
| 66 | UBS GROUP AG | 268.7K -436.9K (-61.9%) | 4.57M -596.8K (-11.6%) | 0.16% -0.270 pp | 0.00% 0.000 pp | USD7.01 +142.5% | 41 qtrs — |
| 67 | D. E. SHAW & CO., INC. | 266.1K +266.1K (+100.0%) | 4.52M +4.5M (+100.0%) | 0.16% +0.159 pp | 0.00% +0.003 pp | USD17.00 +0.0% | 8 qtrs — |
| 68 | TD ASSET MANAGEMENT INC | 252.2K +109.8K (+77.1%) | 4.29M +3.2M (+311.2%) | 0.15% +0.064 pp | 0.00% +0.003 pp | USD11.61 +46.4% | 10 qtrs — |
| 69 | EAM INVESTORS, LLC | 248.8K +248.8K (+100.0%) | 4.23M +4.2M (+100.0%) | 0.15% +0.148 pp | 0.47% +0.471 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 70 | RENAISSANCE TECHNOLOGIES LLC | 236.4K +236.4K (+100.0%) | 4.02M +4.0M (+100.0%) | 0.14% +0.141 pp | 0.01% +0.006 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 71 | BOOTHBAY FUND MANAGEMENT, LLC | 234.8K +113.6K (+93.8%) | 3.99M +3.1M (+350.1%) | 0.14% +0.066 pp | 0.06% +0.047 pp | USD11.56 +47.1% | 8 qtrs — |
| 72 | PLATINUM INVESTMENT MANAGEMENT LTD | 230.7K -37.1K (-13.9%) | 3.92M +2.0M (+100.1%) | 0.14% -0.026 pp | 0.91% +0.780 pp | USD5.62 +202.5% | 32 qtrs — |
| 73 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 230.5K -74.9K (-24.5%) | 3.92M +1.7M (+75.3%) | 0.14% -0.049 pp | 0.06% +0.025 pp | USD6.63 +156.4% | 4 qtrs — |
| 74 | SWISS NATIONAL BANK | 219.7K +8.7K (+4.1%) | 3.73M +2.2M (+141.8%) | 0.13% +0.002 pp | 0.00% +0.001 pp | USD7.29 +133.2% | 9 qtrs — |
| 75 | AQR CAPITAL MANAGEMENT LLC | 202.7K +192.0K (+1,794.9%) | 3.45M +3.4M (+4,300.8%) | 0.12% +0.114 pp | 0.00% +0.002 pp | USD16.49 +3.1% | 10 qtrs — |
| 76 | WELLS FARGO & COMPANY/MN | 200.9K +127.1K (+172.2%) | 3.42M +2.9M (+532.1%) | 0.12% +0.075 pp | 0.00% +0.001 pp | USD13.73 +23.8% | 17 qtrs — |
| 77 | PRIVIUM FUND MANAGEMENT B.V. | 193.0K +23.0K (+13.5%) | 3.28M +2.0M (+163.7%) | 0.12% +0.011 pp | 0.60% +0.380 pp | USD9.73 +74.7% | 6 qtrs — |
| 78 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 182.7K +57.4K (+45.8%) | 3.13M +2.2M (+241.0%) | 0.11% +0.033 pp | 0.00% +0.002 pp | USD10.07 +68.8% | 11 qtrs — |
| 79 | BANK OF AMERICA CORP /DE/ | 182.9K -482.3K (-72.5%) | 3.11M -1.8M (-36.2%) | 0.11% -0.297 pp | 0.00% 0.000 pp | USD8.55 +98.8% | 40 qtrs — |
| 80 | INVESCO LTD. | 179.9K +38.8K (+27.5%) | 3.06M +2.0M (+196.1%) | 0.11% +0.021 pp | 0.00% +0.000 pp | USD8.92 +90.6% | 11 qtrs — |
| 81 | DUQUESNE FAMILY OFFICE LLC | 173.0K +173.0K (+100.0%) | 2.94M +2.9M (+100.0%) | 0.10% +0.103 pp | 0.07% +0.065 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 82 | PRINCIPAL FINANCIAL GROUP INC | 170.2K +170.2K (+100.0%) | 2.89M +2.9M (+100.0%) | 0.10% +0.101 pp | 0.00% +0.002 pp | USD17.00 +0.0% | 7 qtrs — |
| 83 | UBS ASSET MANAGEMENT AMERICAS INC | 165.0K +165.0K (+100.0%) | 2.80M +2.8M (+100.0%) | 0.10% +0.098 pp | 0.00% +0.001 pp | USD17.00 +0.0% | 9 qtrs — |
| 84 | SOFINNOVA INVESTMENTS, INC. | 158.2K -12.8K (-7.5%) | 2.69M +1.4M (+114.9%) | 0.09% -0.010 pp | 0.12% +0.048 pp | USD6.75 +151.9% | 3 qtrs — |
| 85 | BURKEHILL GLOBAL MANAGEMENT, LP | 150.0K +150.0K (+100.0%) | 2.55M +2.6M (+100.0%) | 0.09% +0.089 pp | 0.17% +0.168 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 86 | RHUMBLINE ADVISERS | 141.9K -17.3K (-10.9%) | 2.41M +1.2M (+107.0%) | 0.08% -0.013 pp | 0.00% +0.001 pp | USD5.53 +207.4% | 11 qtrs — |
| 87 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 134.6K +282.0 (+0.2%) | 2.29M +1.3M (+132.7%) | 0.08% -0.002 pp | 0.00% +0.002 pp | USD6.71 +153.4% | 7 qtrs — |
| 88 | BARCLAYS PLC | 124.1K +124.1K (+100.0%) | 2.11M +2.1M (+100.0%) | 0.07% +0.074 pp | 0.00% +0.001 pp | USD17.00 +0.0% | 1 qtrs NEW |
| 89 | ALGERT GLOBAL LLC | 122.5K +122.5K (+100.0%) | 2.08M +2.1M (+100.0%) | 0.07% +0.073 pp | 0.03% +0.033 pp | USD17.00 +0.0% | 5 qtrs — |
| 90 | VOYA INVESTMENT MANAGEMENT LLC | 112.9K -145.1K (-56.3%) | 1.92M +30.2K (+1.6%) | 0.07% -0.090 pp | 0.00% +0.000 pp | USD7.58 +124.3% | 11 qtrs — |
| 91 | ALLIANCEBERNSTEIN L.P. | 112.0K +19.2K (+20.7%) | 1.90M +1.2M (+180.3%) | 0.07% +0.010 pp | 0.00% +0.000 pp | USD9.82 +73.1% | 9 qtrs — |
| 92 | RAYMOND JAMES FINANCIAL INC | 111.2K +95.5K (+608.7%) | 1.89M +1.8M (+1,545.8%) | 0.07% +0.057 pp | 0.00% +0.001 pp | USD16.18 +5.1% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 91 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.61% | 7.61M | 0.35% |
| 2 | F/m Emerald Special Situations ETF SPIT | 1.55% | 449.7K | 0.89% |
| 3 | Roundhill Investments - GLP-1 & Weight Loss ETF OZEM | 0.91% | 580.9K | 0.59% |
| 4 | Global X - Genomics & Biotechnology ETF GNOM | 0.86% | 744.6K | 0.50% |
| 5 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 0.86% | 447.3K | 0.50% |
| 6 | F/M Emerald Life Sciences Innovation ETF LFSC | 0.77% | 574.6K | 0.54% |
| 7 | Virtus Biotech Clinical Trials ETF BBC | 0.66% | 377.2K | 0.65% |
| 8 | ALPS Medical Breakthroughs ETF SBIO | 0.61% | 1.30M | 0.50% |
| 9 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.34% | 78.2K | 1.22% |
| 10 | iShares U.S. Pharmaceuticals ETF IHE | 0.21% | 2.86M | 0.38% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.33
Neutral
Ratio by volume
3.00
Bullish
Buys
16
Sells
12
Shares acquired
14.79M
Shares disposed
4.01M
Cash buys
4.00
Cash sales
8.00
Net activity
+10,785,748
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-09 | Wright Christopher I | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 45,625 | D | ↗ |
| 2026-04-09 | Ingelsson Erik | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 87,864 | D | ↗ |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Ordinary Shares | 971,091 | 6.50 | 6.31M | 26,975,505 | I | ↗ |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Ordinary Shares | 2,495,623 | 6.43 | 16.05M | 26,004,414 | I | ↗ |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Ordinary Shares | 351,224 | 6.38 | 2.24M | 23,508,791 | I | ↗ |
| 2026-03-23 | TAKANASHI KEN | Director | C-Conversion | A | Ordinary Shares | 3,901,348 | 0.00 | — | 9,606,408 | I | ↗ |
| 2026-02-26 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 17,900 | 15.09 | 270.2K | 61,867 | D | ↗ |
| 2026-02-09 | Vargeese Chandra | Officer | S-Sale | D | Ordinary Shares | 3,228 | 13.45 | 43.4K | 408,246 | D | ↗ |
| 2026-02-09 | Moran Kyle | Officer | S-Sale | D | Ordinary Shares | 3,588 | 13.45 | 48.3K | 134,385 | D | ↗ |
| 2026-02-09 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 1,883 | 13.45 | 25.3K | 61,867 | D | ↗ |
| 2026-02-09 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 10,480 | 13.45 | 141.0K | 275,520 | D | ↗ |
| 2026-02-05 | Vargeese Chandra | Officer | A-Award | A | Ordinary Shares | 45,625 | 0.00 | — | 411,474 | D | ↗ |
| 2026-02-05 | Moran Kyle | Officer | A-Award | A | Share Option (right to buy) | 273,750 | 12.75 | 3.49M | 273,750 | D | ↗ |
| 2026-02-05 | Francis Chris | Officer | A-Award | A | Share Option (right to buy) | 232,500 | 12.75 | 2.96M | 232,500 | D | ↗ |
| 2026-02-05 | BOLNO PAUL | Director / Officer | A-Award | A | Share Option (right to buy) | 1,000,000 | 12.75 | 12.75M | 1,000,000 | D | ↗ |
| 2026-01-02 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 8,080 | 15.92 | 128.6K | 26,295 | D | ↗ |
| 2025-12-11 | GSK plc | 10% Owner | P-Purchase | A | Ordinary Shares | 1,470,000 | 19.00 | 27.93M | 18,245,691 | I | ↗ |
| 2025-12-09 | Moran Kyle | Officer | M-Exempt | A | Ordinary Shares | 36,000 | 8.17 | 294.1K | 125,218 | D | ↗ |
| 2025-12-08 | Wagner Heidi L | Director | M-Exempt | D | Share Option (right to buy) | 14,000 | 5.97 | 83.6K | 7,000 | D | ↗ |
| 2025-12-08 | Verdine Gregory L. | Director | S-Sale | D | Ordinary Shares | 12,020 | 13.09 | 157.3K | 283,197 | D | ↗ |
| 2025-12-08 | Tan Aik Na | Director | M-Exempt | A | Ordinary Shares | 45,000 | 4.59 | 206.3K | 70,400 | D | ↗ |
| 2025-12-08 | Rawcliffe Adrian | Director | S-Sale | D | Ordinary Shares | 42,000 | 15.00 | 630.0K | 12,700 | D | ↗ |
| 2025-12-08 | Moran Kyle | Officer | M-Exempt | A | Ordinary Shares | 100,000 | 3.14 | 314.0K | 189,218 | D | ↗ |
| 2025-12-08 | HENRY CHRISTIAN O | Director | M-Exempt | A | Ordinary Shares | 42,000 | 5.97 | 250.7K | 54,700 | D | ↗ |
| 2025-12-08 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 45,882 | 14.50 | 665.3K | 25,000 | D | ↗ |
| 2025-12-08 | CORRIGAN MARK | Director | S-Sale | D | Ordinary Shares | 9,600 | 13.09 | 125.7K | 35,330 | D | ↗ |
| 2025-11-13 | Rawcliffe Adrian | Director | S-Sale | D | Ordinary Shares | 16,115 | 6.79 | 109.4K | 12,700 | D | ↗ |
| 2025-11-13 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Ordinary Shares | 1,000 | 6.69 | 6.7K | 18,203,009 | I | ↗ |
| 2025-08-22 | Verdine Gregory L. | Director | S-Sale | D | Ordinary Shares | 10,000 | 10.00 | 100.0K | 285,217 | D | ↗ |
| 2025-08-22 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 217,351 | 10.10 | 2.19M | 121,000 | D | ↗ |
| 2025-08-15 | Tan Aik Na | Director | S-Sale | D | Ordinary Shares | 21,000 | 9.25 | 194.3K | 40,388 | D | ↗ |
| 2025-08-13 | HENRY CHRISTIAN O | Director | S-Sale | D | Ordinary Shares | 9,670 | 8.81 | 85.2K | 29,645 | D | ↗ |
| 2025-08-11 | Wagner Heidi L | Director | A-Award | A | Share Option (right to buy) | 76,200 | 8.11 | 617.6K | 76,200 | D | ↗ |
| 2025-08-11 | Verdine Gregory L. | Director | A-Award | A | Share Option (right to buy) | 76,200 | 8.11 | 617.6K | 76,200 | D | ↗ |
| 2025-08-11 | Tan Aik Na | Director | A-Award | A | Ordinary Shares | 25,400 | 0.00 | — | 40,388 | D | ↗ |
| 2025-08-11 | TAKANASHI KEN | Director | A-Award | A | Share Option (right to buy) | 76,200 | 8.11 | 617.6K | 76,200 | D | ↗ |
| 2025-08-11 | Rawcliffe Adrian | Director | A-Award | A | Ordinary Shares | 12,700 | 0.00 | — | 28,815 | D | ↗ |
| 2025-08-11 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Ordinary Shares | 12,700 | 0.00 | — | 28,815 | I | ↗ |
| 2025-08-11 | HENRY CHRISTIAN O | Director | A-Award | A | Ordinary Shares | 12,700 | 0.00 | — | 39,315 | D | ↗ |
| 2025-08-11 | CORRIGAN MARK | Director | A-Award | A | Ordinary Shares | 12,700 | 0.00 | — | 44,930 | D | ↗ |
| 2025-08-05 | Tan Aik Na | Director | S-Sale | D | Ordinary Shares | 1,127 | 8.75 | 9.9K | 14,988 | D | ↗ |
| 2025-08-05 | TAKANASHI KEN | Director | S-Sale | D | Ordinary Shares | 4,872 | 8.75 | 42.6K | 5,716,303 | D | ↗ |
| 2025-06-13 | Verdine Gregory L. | Director | S-Sale | D | Ordinary Shares | 30,000 | 6.95 | 208.5K | 282,517 | D | ↗ |
| 2025-03-20 | HENRY CHRISTIAN O | Director | S-Sale | D | Ordinary Shares | 10,500 | 9.77 | 102.6K | 16,115 | D | ↗ |
| 2025-03-07 | Verdine Gregory L. | Director | M-Exempt | A | Ordinary Shares | 133,402 | 2.48 | 330.8K | 312,517 | D | ↗ |
| 2025-03-07 | BOLNO PAUL | Director / Officer | M-Exempt | A | Ordinary Shares | 169,025 | 2.48 | 419.2K | 507,376 | D | ↗ |
| 2025-03-05 | Verdine Gregory L. | Director | M-Exempt | A | Ordinary Shares | 133,000 | 2.48 | 329.8K | 179,155 | D | ↗ |
| 2025-03-04 | Vargeese Chandra | Officer | M-Exempt | A | Ordinary Shares | 91,754 | 2.48 | 227.5K | 362,687 | D | ↗ |
| 2025-02-04 | Vargeese Chandra | Officer | A-Award | A | Share Option (right to buy) | 224,000 | 11.74 | 2.63M | 224,000 | D | ↗ |
| 2025-02-04 | Moran Kyle | Officer | A-Award | A | Ordinary Shares | 42,000 | 0.00 | — | 89,218 | D | ↗ |
| 2025-02-04 | Francis Chris | Officer | A-Award | A | Ordinary Shares | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2025-02-04 | BOLNO PAUL | Director / Officer | A-Award | A | Ordinary Shares | 121,000 | 0.00 | — | 338,351 | D | ↗ |
| 2025-01-23 | Vargeese Chandra | Officer | M-Exempt | A | Ordinary Shares | 46,000 | 2.48 | 114.1K | 233,933 | D | ↗ |
| 2024-11-25 | BOLNO PAUL | Director / Officer | M-Exempt | D | Share Option (right to buy) | 50,000 | 2.48 | 124.0K | 47,778 | D | ↗ |
| 2024-11-15 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 51,234 | 14.32 | 733.7K | 217,351 | D | ↗ |
| 2024-11-08 | Francis Chris | Officer | M-Exempt | A | Ordinary Shares | 36,000 | 8.17 | 294.1K | 36,000 | D | ↗ |
| 2024-10-16 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 79,714 | 14.00 | 1.12M | 0 | D | ↗ |
| 2024-10-16 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 90,474 | 15.00 | 1.36M | 268,585 | D | ↗ |
| 2024-10-11 | Moran Kyle | Officer | M-Exempt | A | Ordinary Shares | 25,000 | 2.48 | 62.0K | 44,777 | D | ↗ |
| 2024-09-27 | GSK plc | 10% Owner | P-Purchase | A | Ordinary Shares | 2,791,930 | 8.00 | 22.34M | 16,775,691 | I | ↗ |
| 2024-09-25 | Moran Kyle | Officer | S-Sale | D | Ordinary Shares | 17,146 | 9.00 | 154.3K | 19,777 | D | ↗ |
| 2024-08-21 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 48,366 | 5.78 | 279.6K | 359,059 | — | ↗ |
| 2024-08-12 | Wagner Heidi L | Director | A-Award | A | Share Option (right to buy) | 64,460 | 5.37 | 346.2K | 64,460 | — | ↗ |
| 2024-08-12 | Verdine Gregory L. | Director | A-Award | A | Ordinary Shares | 16,115 | 0.00 | — | 46,115 | — | ↗ |
| 2024-08-12 | Tan Aik Na | Director | A-Award | A | Ordinary Shares | 16,115 | 0.00 | — | 16,115 | — | ↗ |
| 2024-08-12 | TAKANASHI KEN | Director / 10% Owner | A-Award | A | Ordinary Shares | 16,115 | 0.00 | — | 5,721,175 | — | ↗ |
| 2024-08-12 | Rawcliffe Adrian | Director | A-Award | A | Ordinary Shares | 16,115 | 0.00 | — | 16,115 | — | ↗ |
| 2024-08-12 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Ordinary Shares | 16,115 | 0.00 | — | 16,115 | — | ↗ |
| 2024-08-12 | HENRY CHRISTIAN O | Director | A-Award | A | Ordinary Shares | 16,115 | 0.00 | — | 16,115 | — | ↗ |
| 2024-08-12 | CORRIGAN MARK | Director | A-Award | A | Share Option (right to buy) | 64,460 | 5.37 | 346.2K | 64,460 | — | ↗ |
| 2024-07-22 | Vargeese Chandra | Officer | M-Exempt | A | Ordinary Shares | 68,210 | 2.48 | 169.2K | 185,061 | — | ↗ |
| 2024-04-03 | Moran Kyle | Officer | S-Sale | D | Ordinary Shares | 15,630 | 6.17 | 96.4K | 33,921 | — | ↗ |
| 2024-02-05 | Vargeese Chandra | Officer | A-Award | A | Share Option (right to buy) | 361,700 | 3.87 | 1.40M | 361,700 | — | ↗ |
| 2024-02-05 | Moran Kyle | Officer | A-Award | A | Share Option (right to buy) | 371,500 | 3.87 | 1.44M | 371,500 | — | ↗ |
| 2024-02-05 | Francis Chris | Officer | A-Award | A | Share Option (right to buy) | 286,400 | 3.87 | 1.11M | 286,400 | — | ↗ |
| 2024-02-05 | BOLNO PAUL | Director / Officer | A-Award | A | Share Option (right to buy) | 1,008,600 | 3.87 | 3.90M | 1,008,600 | — | ↗ |
| 2023-12-11 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000,000 | 5.00 | 5.00M | 18,202,009 | — | ↗ |
| 2023-12-07 | GSK plc | 10% Owner | P-Purchase | A | Ordinary Shares | 3,300,000 | 5.00 | 16.50M | 13,983,761 | — | ↗ |
| 2023-08-23 | Moran Kyle | Officer | S-Sale | D | Ordinary Shares | 37,062 | 4.75 | 176.1K | 46,120 | — | ↗ |
| 2023-08-07 | Wagner Heidi L | Director | A-Award | A | Share Option (right to buy) | 45,000 | 4.58 | 206.1K | 45,000 | — | ↗ |
| 2023-08-07 | Verdine Gregory L. | Director | A-Award | A | Share Option (right to buy) | 45,000 | 4.58 | 206.1K | 45,000 | — | ↗ |
| 2023-08-07 | Tan Aik Na | Director | A-Award | A | Share Option (right to buy) | 45,000 | 4.58 | 206.1K | 45,000 | — | ↗ |
| 2023-08-07 | TAKANASHI KEN | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 45,000 | 4.58 | 206.1K | 45,000 | — | ↗ |
| 2023-08-07 | Rawcliffe Adrian | Director | A-Award | A | Share Option (right to buy) | 45,000 | 4.58 | 206.1K | 45,000 | — | ↗ |
| 2023-08-07 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Share Option (Right to Buy) | 45,000 | 4.58 | 206.1K | 45,000 | — | ↗ |
| 2023-08-07 | HENRY CHRISTIAN O | Director | A-Award | A | Share Option (right to buy) | 45,000 | 4.58 | 206.1K | 45,000 | — | ↗ |
| 2023-08-07 | CORRIGAN MARK | Director | A-Award | A | Share Option (right to buy) | 45,000 | 4.58 | 206.1K | 45,000 | — | ↗ |
| 2023-02-17 | Vargeese Chandra | Officer | A-Award | A | Share Option (right to buy) | 295,400 | 4.75 | 1.40M | 295,400 | — | ↗ |
| 2023-02-17 | Moran Kyle | Officer | A-Award | A | Share Option (right to buy) | 272,700 | 4.75 | 1.30M | 272,700 | — | ↗ |
| 2023-02-17 | Francis Chris | Officer | A-Award | A | Share Option (right to buy) | 244,700 | 4.75 | 1.16M | 244,700 | — | ↗ |
| 2023-02-17 | BOLNO PAUL | Director / Officer | A-Award | A | Share Option (right to buy) | 771,000 | 4.75 | 3.66M | 771,000 | — | ↗ |
| 2023-02-16 | Vargeese Chandra | Officer | S-Sale | D | Ordinary Shares | 10,249 | 4.03 | 41.3K | 106,624 | — | ↗ |
| 2023-02-16 | Moran Kyle | Officer | S-Sale | D | Ordinary Shares | 9,729 | 4.04 | 39.3K | 79,751 | — | ↗ |
| 2023-02-16 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 10,258 | 4.03 | 41.3K | 79,714 | — | ↗ |
| 2023-02-16 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 29,400 | 4.04 | 118.8K | 407,425 | — | ↗ |
| 2023-01-23 | GSK PLC | Director | — | I | Ordinary Shares | 0 | 0.00 | — | 10,683,761 | — | ↗ |
| 2022-10-27 | Verdine Gregory L. | Director | A-Award | A | Share Option (right to buy) | 163,467 | 0.00 | — | 163,467 | — | ↗ |
| 2022-08-15 | Wagner Heidi L | Director | A-Award | A | Share Option (right to buy) | 21,000 | 3.50 | 73.5K | 21,000 | — | ↗ |
| 2022-08-15 | Verdine Gregory L. | Director | A-Award | A | Share Option (right to buy) | 21,000 | 3.50 | 73.5K | 21,000 | — | ↗ |
| 2022-08-15 | Tan Aik Na | Director | A-Award | A | Share Option (right to buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-08-15 | TAKANASHI KEN | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 21,000 | 3.50 | 73.5K | 21,000 | — | ↗ |
| 2022-08-15 | Shah Rajeev M. | Director | A-Award | A | Share Option (right to buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-08-15 | Rawcliffe Adrian | Director | A-Award | A | Share Option (right to buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-08-15 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 21,000 | 3.50 | 73.5K | 21,000 | — | ↗ |
| 2022-08-15 | HENRY CHRISTIAN O | Director | A-Award | A | Share Option (right to buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-08-15 | CORRIGAN MARK | Director | A-Award | A | Share Option (right to buy) | 21,000 | 3.50 | 73.5K | 21,000 | — | ↗ |
| 2022-07-25 | Vargeese Chandra | Officer | A-Award | A | Share Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-07-25 | Panzara Michael A. | Officer | A-Award | A | Share Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-07-25 | Moran Kyle | Officer | A-Award | A | Share Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-07-25 | Francis Chris | Officer | A-Award | A | Share Option (right to buy) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-07-25 | BOLNO PAUL | Director / Officer | A-Award | A | Share Option (right to buy) | 180,000 | 2.83 | 509.4K | 180,000 | — | ↗ |
| 2022-06-16 | Shah Rajeev M. | Director | P-Purchase | A | Pre-Funded Warrants (Right to Buy) | 7,093,656 | 2.15 | 15.25M | 7,093,656 | — | ↗ |
| 2022-06-16 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Ordinary Shares | 9,480,052 | 2.15 | 20.38M | 17,202,009 | — | ↗ |
| 2022-05-04 | Vargeese Chandra | Officer | A-Award | A | Ordinary Shares | 50,000 | 0.00 | — | 127,809 | — | ↗ |
| 2022-05-04 | Panzara Michael A. | Officer | S-Sale | D | Ordinary Shares | 16,714 | 1.72 | 28.7K | 109,103 | — | ↗ |
| 2022-05-04 | Moran Kyle | Officer | A-Award | A | Ordinary Shares | 15,000 | 0.00 | — | 89,588 | — | ↗ |
| 2022-05-04 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 10,867 | 1.72 | 18.7K | 89,972 | — | ↗ |
| 2022-05-04 | BOLNO PAUL | Officer | S-Sale | D | Ordinary Shares | 33,501 | 1.72 | 57.6K | 436,825 | — | ↗ |
| 2022-02-16 | Vargeese Chandra | Officer | S-Sale | D | Ordinary Shares | 10,603 | 2.32 | 24.6K | 77,809 | — | ↗ |
| 2022-02-16 | Panzara Michael A. | Officer | S-Sale | D | Ordinary Shares | 10,603 | 2.31 | 24.5K | 75,817 | — | ↗ |
| 2022-02-16 | Moran Kyle | Officer | S-Sale | D | Ordinary Shares | 9,204 | 2.31 | 21.3K | 74,588 | — | ↗ |
| 2022-02-16 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 10,123 | 2.31 | 23.4K | 68,339 | — | ↗ |
| 2022-02-16 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 33,150 | 2.32 | 76.9K | 377,826 | — | ↗ |
| 2022-01-01 | Vargeese Chandra | Officer | A-Award | A | Share Option (right to buy) | 200,000 | 3.14 | 628.0K | 200,000 | — | ↗ |
| 2022-01-01 | Panzara Michael A. | Officer | A-Award | A | Share Option (right to buy) | 200,000 | 3.14 | 628.0K | 200,000 | — | ↗ |
| 2022-01-01 | Moran Kyle | Officer | A-Award | A | Share Option (right to buy) | 175,000 | 3.14 | 549.5K | 175,000 | — | ↗ |
| 2022-01-01 | Francis Chris | Officer | A-Award | A | Share Option (right to buy) | 150,000 | 3.14 | 471.0K | 150,000 | — | ↗ |
| 2022-01-01 | BOLNO PAUL | Director / Officer | A-Award | A | Share Option (right to buy) | 600,000 | 3.14 | 1.88M | 600,000 | — | ↗ |
| 2021-08-16 | Wagner Heidi L | Director | A-Award | A | Share Option (right to buy) | 21,000 | 5.97 | 125.4K | 21,000 | — | ↗ |
| 2021-08-16 | Verdine Gregory L. | Director | A-Award | A | Share Option (right to buy) | 42,000 | 5.97 | 250.7K | 42,000 | — | ↗ |
| 2021-08-16 | Tan Aik Na | Director | A-Award | A | Share Option (right to buy) | 21,000 | 5.97 | 125.4K | 21,000 | — | ↗ |
| 2021-08-16 | TAKANASHI KEN | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 42,000 | 5.97 | 250.7K | 42,000 | — | ↗ |
| 2021-08-16 | Rawcliffe Adrian | Director | A-Award | A | Share Option (right to buy) | 42,000 | 5.97 | 250.7K | 42,000 | — | ↗ |
| 2021-08-16 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 42,000 | 5.97 | 250.7K | 42,000 | — | ↗ |
| 2021-08-16 | HENRY CHRISTIAN O | Director | A-Award | A | Share Option (right to buy) | 42,000 | 5.97 | 250.7K | 42,000 | — | ↗ |
| 2021-08-16 | CORRIGAN MARK | Director | A-Award | A | Share Option (right to buy) | 21,000 | 5.97 | 125.4K | 21,000 | — | ↗ |
| 2021-04-01 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | J-Other | A | Ordinary Shares | 768,431 | 5.61 | 4.31M | 7,573,613 | — | ↗ |
| 2021-03-24 | Moran Kyle | Officer | M-Exempt | A | Ordinary Shares | 10,930 | 2.48 | 27.1K | 80,792 | — | ↗ |
| 2021-02-16 | Vargeese Chandra | Officer | S-Sale | D | Ordinary Shares | 3,145 | 10.57 | 33.2K | 85,412 | — | ↗ |
| 2021-02-16 | Panzara Michael A. | Officer | S-Sale | D | Ordinary Shares | 2,929 | 10.57 | 31.0K | 86,420 | — | ↗ |
| 2021-02-16 | Moran Kyle | Officer | S-Sale | D | Ordinary Shares | 1,722 | 10.57 | 18.2K | 69,862 | — | ↗ |
| 2021-02-16 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 2,698 | 10.57 | 28.5K | 78,462 | — | ↗ |
| 2021-02-16 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 11,205 | 10.57 | 118.4K | 410,976 | — | ↗ |
| 2021-02-01 | Vargeese Chandra | Officer | A-Award | A | Ordinary Shares | 50,000 | 0.00 | — | 88,557 | — | ↗ |
| 2021-02-01 | Panzara Michael A. | Officer | A-Award | A | Ordinary Shares | 50,000 | 0.00 | — | 89,349 | — | ↗ |
| 2021-02-01 | Moran Kyle | Officer | A-Award | A | Ordinary Shares | 50,000 | 0.00 | — | 71,584 | — | ↗ |
| 2021-02-01 | Francis Chris | Officer | A-Award | A | Share Option (right to buy) | 50,000 | 10.48 | 524.0K | 50,000 | — | ↗ |
| 2021-02-01 | BOLNO PAUL | Director / Officer | A-Award | A | Ordinary Shares | 150,000 | 0.00 | — | 422,181 | — | ↗ |
| 2020-12-05 | Moran Kyle | Officer | — | D | Share Option (Right to Buy) | 36,000 | 8.17 | 294.1K | 0 | — | ↗ |
| 2020-09-15 | BOLNO PAUL | Director / Officer | M-Exempt | A | Ordinary Shares | 100,000 | 2.48 | 248.0K | 372,181 | — | ↗ |
| 2020-08-25 | BOLNO PAUL | Director / Officer | M-Exempt | A | Ordinary Shares | 25,000 | 2.48 | 62.0K | 297,181 | — | ↗ |
| 2020-08-18 | Wagner Heidi L | Director | A-Award | A | Share Option (right to buy) | 10,500 | 9.13 | 95.9K | 10,500 | — | ↗ |
| 2020-08-18 | Verdine Gregory L. | Director | A-Award | A | Share Option (right to buy) | 10,500 | 9.13 | 95.9K | 10,500 | — | ↗ |
| 2020-08-18 | Tan Aik Na | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-18 | TAKANASHI KEN | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 10,500 | 9.13 | 95.9K | 10,500 | — | ↗ |
| 2020-08-18 | Rawcliffe Adrian | Director | A-Award | A | Share Option (right to buy) | 10,500 | 9.13 | 95.9K | 10,500 | — | ↗ |
| 2020-08-18 | Pott Amy | Director | A-Award | A | Share Option (right to buy) | 10,500 | 9.13 | 95.9K | 10,500 | — | ↗ |
| 2020-08-18 | Kolchinsky Peter | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 10,500 | 9.13 | 95.9K | 10,500 | — | ↗ |
| 2020-08-18 | HENRY CHRISTIAN O | Director | A-Award | A | Share Option (right to buy) | 10,500 | 9.13 | 95.9K | 10,500 | — | ↗ |
| 2020-08-18 | CORRIGAN MARK | Director | A-Award | A | Share Option (right to buy) | 10,500 | 9.13 | 95.9K | 10,500 | — | ↗ |
| 2020-07-02 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 4,509 | 10.82 | 48.8K | 315,249 | — | ↗ |
| 2020-03-03 | Vargeese Chandra | Officer | A-Award | A | Share Option (right to buy) | 36,000 | 8.17 | 294.1K | 36,000 | — | ↗ |
| 2020-03-03 | Panzara Michael A. | Officer | A-Award | A | Share Option (right to buy) | 36,000 | 8.17 | 294.1K | 36,000 | — | ↗ |
| 2020-03-03 | Gaiero David G | Officer | A-Award | A | Share Option (right to buy) | 18,000 | 8.17 | 147.1K | 18,000 | — | ↗ |
| 2020-03-03 | Francis Chris | Officer | A-Award | A | Share Option (right to buy) | 36,000 | 8.17 | 294.1K | 36,000 | — | ↗ |
| 2020-03-03 | BOLNO PAUL | Director / Officer | A-Award | A | Share Option (right to buy) | 63,000 | 8.17 | 514.7K | 63,000 | — | ↗ |
| 2020-02-18 | Vargeese Chandra | Officer | S-Sale | D | Ordinary Shares | 3,188 | 7.85 | 25.0K | 37,057 | — | ↗ |
| 2020-02-18 | Panzara Michael A. | Officer | S-Sale | D | Ordinary Shares | 2,981 | 7.85 | 23.4K | 39,349 | — | ↗ |
| 2020-02-18 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 2,708 | 7.85 | 21.3K | 31,160 | — | ↗ |
| 2020-02-18 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 11,451 | 7.85 | 89.9K | 319,758 | — | ↗ |
| 2020-02-03 | Gaiero David G | Officer | S-Sale | D | Ordinary Shares | 651 | 7.00 | 4.6K | 6,392 | — | ↗ |
| 2020-01-09 | Gaiero David G | Officer | — | D | Ordinary Shares | 0 | 0.00 | — | 7,043 | — | ↗ |
| 2019-12-03 | Vargeese Chandra | Officer | M-Exempt | D | Share Option (right to buy) | 6,000 | 2.48 | 14.9K | 143,542 | — | ↗ |
| 2019-11-20 | Verdine Gregory L. | Director | S-Sale | D | Ordinary Shares | 3,400 | 31.59 | 107.4K | 32,609 | — | ↗ |
| 2019-09-04 | Wagner Heidi L | Director | A-Award | A | Share Option (right to buy) | 21,000 | 21.03 | 441.6K | 21,000 | — | ↗ |
| 2019-09-04 | Pott Amy | Director | A-Award | A | Share Option (right to buy) | 21,000 | 21.03 | 441.6K | 21,000 | — | ↗ |
| 2019-09-04 | CORRIGAN MARK | Director | A-Award | A | Share Option (right to buy) | 21,000 | 21.03 | 441.6K | 21,000 | — | ↗ |
| 2019-08-15 | Verdine Gregory L. | Director | A-Award | A | Share Option (right to buy) | 10,500 | 20.34 | 213.6K | 10,500 | — | ↗ |
| 2019-08-15 | TAKANASHI KEN | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 10,500 | 20.34 | 213.6K | 10,500 | — | ↗ |
| 2019-08-15 | Rawcliffe Adrian | Director | A-Award | A | Share Option (right to buy) | 10,500 | 20.34 | 213.6K | 10,500 | — | ↗ |
| 2019-08-15 | Miura Koji | Director | A-Award | A | Share Option (right to buy) | 10,500 | 20.34 | 213.6K | 10,500 | — | ↗ |
| 2019-08-15 | Kolchinsky Peter | Director / 10% Owner | A-Award | A | Share Option (right to buy) | 10,500 | 20.34 | 213.6K | 10,500 | — | ↗ |
| 2019-08-15 | HENRY CHRISTIAN O | Director | A-Award | A | Share Option (right to buy) | 10,500 | 20.34 | 213.6K | 10,500 | — | ↗ |
| 2019-08-05 | Baldry Mark | Officer | A-Award | A | Ordinary Shares | 4,000 | 0.00 | — | 39,000 | — | ↗ |
| 2019-07-05 | Panzara Michael A. | Officer | S-Sale | D | Ordinary Shares | 2,613 | 26.88 | 70.2K | 42,775 | — | ↗ |
| 2019-03-15 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 5,065 | 45.89 | 232.4K | 341,209 | — | ↗ |
| 2019-03-11 | Panzara Michael A. | Officer | S-Sale | D | Ordinary Shares | 7,000 | 48.00 | 336.0K | 45,388 | — | ↗ |
| 2019-03-07 | Vargeese Chandra | Officer | A-Award | A | Ordinary Shares | 15,000 | 0.00 | — | 40,245 | — | ↗ |
| 2019-03-07 | Regnante Keith | Officer | A-Award | A | Ordinary Shares | 13,500 | 0.00 | — | 29,186 | — | ↗ |
| 2019-03-07 | Panzara Michael A. | Officer | A-Award | A | Ordinary Shares | 15,000 | 0.00 | — | 52,388 | — | ↗ |
| 2019-03-07 | Francis Chris | Officer | A-Award | A | Ordinary Shares | 13,500 | 0.00 | — | 33,868 | — | ↗ |
| 2019-03-07 | BOLNO PAUL | Director / Officer | A-Award | A | Ordinary Shares | 60,000 | 0.00 | — | 331,209 | — | ↗ |
| 2019-02-19 | Vargeese Chandra | Officer | S-Sale | D | Ordinary Shares | 2,055 | 36.84 | 75.7K | 25,245 | — | ↗ |
| 2019-02-19 | Regnante Keith | Officer | S-Sale | D | Ordinary Shares | 1,298 | 36.84 | 47.8K | 15,686 | — | ↗ |
| 2019-02-19 | Panzara Michael A. | Officer | S-Sale | D | Ordinary Shares | 1,837 | 36.84 | 67.7K | 37,388 | — | ↗ |
| 2019-02-19 | Francis Chris | Officer | S-Sale | D | Ordinary Shares | 1,709 | 36.84 | 63.0K | 20,368 | — | ↗ |
| 2019-02-19 | BOLNO PAUL | Director / Officer | S-Sale | D | Ordinary Shares | 7,614 | 36.38 | 277.0K | 271,328 | — | ↗ |
| 2019-01-24 | RA CAPITAL MANAGEMENT, LLC | Director / 10% Owner | P-Purchase | A | Ordinary Shares | 263,158 | 38.00 | 10.00M | 7,775,207 | — | ↗ |
| 2018-11-14 | Verdine Gregory L. | Director | S-Sale | D | Ordinary Shares | 10,700 | 38.59 | 412.9K | 64,339 | — | ↗ |
| 2018-09-25 | Francis Chris | Officer | M-Exempt | A | Ordinary Shares | 10,543 | 2.48 | 26.1K | 32,620 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-6.4K
Shares Outstanding
192.40M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 655.5K | — | — | 3.06M | 532.6K | 19.3K | 4.27M | 71.74% | ↗ |
| 2 | 2024 | Kyle Moran, CFA Chief Financial Officer | 497.2K | — | — | 1.13M | 279.7K | 11.6K | 1.92M | 58.88% | ↗ |
| 3 | 2024 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 487.5K | — | — | 1.10M | 288.0K | 13.9K | 1.89M | 58.20% | ↗ |
| 4 | 2024 | Christopher Francis, Ph.D. Senior Vice President, Corporate Development and Head of Emerging Areas | 438.3K | — | — | 870.3K | 246.6K | 11.3K | 1.57M | 55.56% | ↗ |
| 5 | 2023 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 636.4K | — | — | 2.74M | 475.7K | 17.7K | 3.87M | 70.84% | ↗ |
| 6 | 2023 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 473.3K | — | — | 1.05M | 245.0K | 13.5K | 1.78M | 58.96% | ↗ |
| 7 | 2023 | Kyle Moran, CFA Chief Financial Officer | 471.3K | — | — | 970.7K | 243.9K | 11.1K | 1.70M | 57.20% | ↗ |
| 8 | 2023 | Christopher Francis, Ph.D. Senior Vice President, Corporate Development and Head of Emerging Areas | 425.5K | — | — | 871.1K | 220.2K | 10.7K | 1.53M | 57.03% | ↗ |
| 9 | 2022 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 617.9K | — | — | 1.57M | 461.9K | 23.0K | 2.67M | 58.67% | ↗ |
| 10 | 2022 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 459.5K | — | — | 521.7K | 237.8K | 12.7K | 1.23M | 42.36% | ↗ |
| 11 | 2022 | Kyle Moran, CFA Chief Financial Officer | 439.9K | — | — | 470.9K | 227.6K | 10.4K | 1.15M | 40.99% | ↗ |
| 12 | 2022 | Christopher Francis, Ph.D. Senior Vice President, Corporate Development and Head of Emerging Areas | 407.8K | — | — | 391.3K | 211.0K | 540.00 | 1.01M | 38.72% | ↗ |
| 13 | 2021 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 597.0K | — | 1.57M | 1.33M | 388.1K | 9.5K | 3.89M | 74.45% | ↗ |
| 14 | 2021 | Michael Panzara, M.D., MPH Chief Medical Officer, Head of Therapeutics Discovery and Development | 471.0K | — | 524.0K | 331.5K | 212.0K | 9.9K | 1.55M | 55.25% | ↗ |
| 15 | 2021 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 444.0K | — | 524.0K | 331.5K | 199.8K | 12.3K | 1.51M | 56.60% | ↗ |
| 16 | 2020 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 579.0K | — | — | 308.7K | 376.3K | 6.2K | 1.27M | 24.30% | ↗ |
| 17 | 2020 | Michael Panzara, M.D., MPH Chief Medical Officer, Head of Therapeutics Discovery and Development | 460.9K | — | — | 176.4K | 184.3K | 9.8K | 831.4K | 21.22% | ↗ |
| 18 | 2020 | Chandra Vargeese, Ph.D. Chief Technology Officer | 434.5K | — | — | 176.4K | 173.8K | 10.9K | 795.6K | 22.17% | ↗ |
| 19 | 2020 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 434.5K | — | — | 176.4K | 173.8K | 10.9K | 795.6K | 22.17% | ↗ |
| 20 | 2019 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 579.0K | — | 2.70M | — | 282.3K | 20.3K | 3.58M | 75.39% | ↗ |
| 21 | 2019 | Mark Baldry Former Chief Commercial Officer | 173.5K | 80.0K | 759.7K | 311.6K | 52.0K | 178.0K | 1.55M | 68.90% | ↗ |
| 22 | 2019 | Michael Panzara, M.D., MPH Chief Medical Officer, Head of Therapeutics Discovery and Development | 451.8K | — | 675.0K | — | 135.5K | 9.6K | 1.27M | 53.07% | ↗ |
| 23 | 2019 | Michael Panzara, M.D., MPH Chief Medical Officer | 451.8K | — | 675.0K | — | 135.5K | 9.6K | 1.27M | 53.07% | ↗ |
| 24 | 2019 | Chandra Vargeese, Ph.D. Chief Technology Officer | 426.0K | — | 675.0K | — | 127.8K | 10.7K | 1.24M | 54.46% | ↗ |
| 25 | 2019 | Keith C. Regnante Former Chief Financial Officer | 362.3K | — | 607.5K | — | 108.7K | 9.6K | 1.09M | 55.83% | ↗ |
| 26 | 2018 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 541.1K | — | 2.18M | 2.80M | 303.6K | 10.0K | 5.84M | 85.37% | ↗ |
| 27 | 2018 | Michael Panzara, M.D., MPH Chief Medical Officer | 430.3K | — | 700.9K | 899.9K | 175.6K | 9.5K | 2.22M | 72.23% | ↗ |
| 28 | 2018 | Chandra Vargeese, Ph.D. Chief Technology Officer | 400.0K | — | 700.9K | 899.9K | 163.2K | 10.6K | 2.17M | 73.61% | ↗ |
| 29 | 2018 | Chandra Vargeese, Ph.D. Senior Vice President, Drug Discovery | 400.0K | — | 700.9K | 899.9K | 163.2K | 10.6K | 2.17M | 73.61% | ↗ |
| 30 | 2018 | Keith C. Regnante Chief Financial Officer | 350.0K | — | 520.7K | 668.5K | 142.8K | 9.1K | 1.69M | 70.32% | ↗ |
| 31 | 2018 | Keith C. Regnante Former Chief Financial Officer | 350.0K | — | 520.7K | 668.5K | 142.8K | 9.1K | 1.69M | 70.32% | ↗ |
| 32 | 2018 | Christopher Francis, Ph.D. Senior Vice President, Corporate Development, Head of Emerging Areas | 363.0K | — | 520.7K | 668.5K | 129.6K | 540.00 | 1.68M | 70.69% | ↗ |
| 33 | 2017 | Paul B. Bolno, M.D. President and Chief Executive Officer | 515.3K | — | 1.05M | 1.34M | 283.4K | 528.00 | 3.20M | 75.00% | ↗ |
| 34 | 2017 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 515.3K | — | 1.05M | 1.34M | 283.4K | 528.00 | 3.20M | 75.00% | ↗ |
| 35 | 2017 | Chandra Vargeese, Ph.D. Chief Technology Officer | 350.0K | — | 284.7K | 361.2K | 154.0K | 7.4K | 1.16M | 55.81% | ↗ |
| 36 | 2017 | Chandra Vargeese, Ph.D. Senior Vice President, Drug Discovery | 350.0K | — | 284.7K | 361.2K | 154.0K | 7.4K | 1.16M | 55.81% | ↗ |
| 37 | 2017 | Christopher Francis, Ph.D. Senior Vice President, Corporate Development, Head of Emerging Areas | 330.0K | — | 284.7K | 361.2K | 127.1K | 528.00 | 1.10M | 58.53% | ↗ |
| 38 | 2017 | Michael Panzara, M.D., MPH Chief Medical Officer | 417.8K | — | 200.4K | 255.6K | 183.8K | 9.3K | 1.07M | 42.74% | ↗ |
| 39 | 2017 | Keith C. Regnante Chief Financial Officer | 327.4K | — | 124.9K | 159.3K | 144.1K | 6.1K | 761.8K | 37.31% | ↗ |
| 40 | 2017 | Keith C. Regnante Former Chief Financial Officer | 327.4K | — | 124.9K | 159.3K | 144.1K | 6.1K | 761.8K | 37.31% | ↗ |
| 41 | 2016 | Paul B. Bolno, M.D. President and Chief Executive Officer | 490.0K | 329.0K | — | 2.51M | 245.0K | 25.5K | 3.59M | 69.69% | ↗ |
| 42 | 2016 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 490.0K | 329.0K | — | 2.51M | 245.0K | 25.5K | 3.59M | 69.69% | ↗ |
| 43 | 2016 | Michael Panzara, M.D., MPH Chief Medical Officer | 193.5K | 55.0K | 493.4K | 1.86M | 162.2K | 496.00 | 2.76M | 85.11% | ↗ |
| 44 | 2016 | Michael Panzara, M.D. | 193.5K | 55.0K | 493.4K | 1.86M | 162.2K | 496.00 | 2.76M | 85.11% | ↗ |
| 45 | 2016 | Franchise Lead, Neurology Keith C. Regnante. Chief Financial Officer | 120.0K | — | — | 1.47M | 48.3K | 331.00 | 1.64M | 89.71% | ↗ |
| 46 | 2016 | Keith C. Regnante Chief Financial Officer | 120.0K | — | — | 1.47M | 48.3K | 331.00 | 1.64M | 89.71% | ↗ |
| 47 | 2015 | Paul B. Bolno, M.D. President and Chief Executive Officer | 450.0K | 112.5K | 842.0K | 1.74M | 112.5K | 397.00 | 3.26M | 79.29% | ↗ |
| 48 | 2015 | Chandra Vargeese, Ph.D. Senior Vice President, Head of Drug Discovery | 285.0K | 71.3K | — | 710.4K | 71.3K | 397.00 | 1.14M | 62.41% | ↗ |
| 49 | 2015 | Christopher Francis, Ph.D. Vice President, Head of Business Development | 185.0K | 46.3K | — | 470.7K | 46.3K | 397.00 | 748.6K | 62.88% | ↗ |
| 50 | 2014 | Paul B. Bolno, M.D. President and Chief Executive Officer | 450.0K | — | — | — | 112.5K | 71.00 | 562.6K | 0.00% | ↗ |
| 51 | 2014 | Christopher Francis, Ph.D. Vice President, Head of Business Development | 131.0K | — | — | — | 29.7K | 50.00 | 160.8K | 0.00% | ↗ |
| 52 | 2014 | Chandra Vargeese, Ph.D. Senior Vice President, Head of Drug Discovery | 118.8K | — | — | — | 32.9K | 29.00 | 151.7K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul Bolno | President, Chief Executive Officer & Director | 1M | — |
| Kyle Moran | Chief Financial Officer & Principal Accounting Officer | 864.7K | male |
| Chandra Vargeese | Chief Technology Officer | 836.6K | — |
| Christopher Francis | Senior Vice President of Corporate Development & Head of Emerging Areas | 736.9K | — |
| Gregory L. Verdine | Founder & Director | 49.4K | — |
| Sridhar Vaddeboina | Senior Vice President of Chemistry, Manufacturing & Controls | — | — |
| Daryn Lewis | Senior Vice President & Head of Human Resources | — | female |
| Erik Ingelsson | Chief Scientific Officer | — | — |
| Kate Rausch | Head of Investor Relations | — | female |
| Linda Rockett | Senior Vice President & General Counsel | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WVE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
